ZBH's growth outlook is backed by healthy procedure demand and Z1, HAMMR and OrthoGrid adoption, though debt and competition remain concerns.

Zimmer Biomet Holdings has seen its share price decline about 27.9% over the past five years, yet the stock still screens as attractively priced on several valuation checks. This raises questions for investors trying to reconcile weak long term returns with a more positive current valuation read. Over the past five years the stock has declined about 27.9%, which signals that long term holders have not yet been rewarded despite the recent rebound. The ongoing shift to a fully dedicated sales...

ISRG's software roadmap is strengthening da Vinci 5, with new features, renewals and recurring service revenues reinforcing its digital ecosystem.

Stryker has gained 3.8% since March-end as Mako robotics, hospital capital demand and international growth drive momentum.

Zimmer Biomet has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

Zimmer Biomet’s second quarter results were driven by strong execution in its hip franchise, robust technology sales, and progress in the U.S. sales force transformation. CEO Ivan Tornos highlighted that new product adoption, such as the Z1 hip stem and OrthoGrid navigation, contributed to above-average growth in the U.S. In addition, increased demand for the company’s technology and data solutions, including capital equipment sales, played a key role. Management attributed the quarter’s perform

Stryker's 13.6% three-month rally reflects stronger sales, margins and production, but execution risks and a premium peer valuation could test further gains.

Stryker's stronger growth, margin gains and product pipeline support the case, but cyber costs, supply constraints and acquisition execution keep risks elevated.

Stryker enters the second half with Q2 momentum restored, but meeting guidance hinges on production, backlog conversion and managing cyber and supply risks.

Get paid a real income now on your Intuitive Surgical shares—income you keep no matter what—in exchange for agreeing to sell at a higher price if the stock gets there.

Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years.

Management raised full-year guidance on strong hip and technology segment growth.

Zimmer Biomet (NYSE:ZBH) reported second-quarter 2026 net sales of $2.177 billion, up 4.8% on a reported basis and 4.0% on an organic constant-currency basis, as growth in hips, specialty businesses and technology helped offset weaker performance in certain other product lines. U.S. organic constan

Zimmer Biomet Holdings (ZBH) just paired stronger than expected quarterly results with a guidance increase, as management pointed to solid execution in U.S. hip and technology lines and progress in its sales force restructuring. See our latest analysis for Zimmer Biomet Holdings. Zimmer Biomet Holdings' recent guidance lift and Q2 beat come after a period of mixed returns, with the share price at US$97.19 and a 90-day share price return of 18.05%. However, the 5-year total shareholder return...

Zimmer Biomet Holdings is back in focus as analysts fine tune their price targets around recent research and earnings news. Targets such as US$110, US$95 and US$93 reflect a mix of supportive and cautious views on how the current share price lines up with execution and growth expectations. As you read on, you will see how these moves fit into the evolving narrative and what to watch next to stay on top of sentiment around Zimmer Biomet Holdings. Stay updated as the Fair Value for Zimmer...

Boston Scientific's 2026 guidance cut tests its recovery as WATCHMAN weakness, EP share losses and delayed margin gains push a broader rebound toward 2028.

The restructuring, intended to give Zimmer Biomet a fully dedicated sales force, is expected to be complete by the end of 2027.

Zimmer Biomet Holdings Inc (ZBH) raises full-year outlook on robust US hip and technology growth, while navigating ongoing commercial transformation and international headwinds.

Moby summary of Zimmer Biomet Holdings, Inc.'s Q2 2026 earnings call

Zimmer released its Q2 financials ahead of market open, prompting its shares on the New York Stock Exchange to rise by over 5% at market open on 5 August.

ZBH beats second-quarter earnings and revenue estimates, raises its 2026 outlook and gains in pre-market despite pressure on adjusted margins.

While the top- and bottom-line numbers for Zimmer (ZBH) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zimmer Biomet Holdings (NYSE:ZBH) reported better-than-expected second-quarter results and increased its guidance for the full year, helping lift the medical technology company’s shares more than 4% in pre-market trading. The company posted adjusted earnings of $2.

Zimmer (ZBH) delivered earnings and revenue surprises of +2.99% and +2.25%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Medical device company Zimmer Biomet (NYSE:ZBH) announced better-than-expected revenue in Q2 CY2026, with sales up 4.8% year on year to $2.18 billion. Its non-GAAP profit of $2.07 per share was 3% above analysts’ consensus estimates.

Pacira BioSciences (NASDAQ:PCRX) reported second-quarter 2026 revenue growth, led by higher sales of its EXPAREL, ZILRETTA and iovera° products, while highlighting expanded payer coverage, pipeline progress and the completed sale of iovera° to Zimmer Biomet. Total second-quarter revenue rose 6% fro

Can Zimmer Biomet, Charles River Laboratories and Bio-Techne meet earnings expectations? See the MedTech trends and company-specific drivers in focus.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 16.6% over the past six months, topping the S&P 500 by 9.6 percentage points.

ISRG is expanding robotic surgery beyond urology as general surgery and newer specialties gain traction, creating fresh avenues for long-term procedure growth.

Neogen (NEOG) delivered earnings and revenue surprises of +80.00% and +6.29%, respectively, for the quarter ended May 2026. Do the numbers hold clues to what lies ahead for the stock?

Earlier this year, Zimmer Biomet reported a strong first quarter, with revenue rising 9.3% year on year and both sales and earnings surpassing analysts’ expectations. Management’s confident comments that the company is off to a solid strategic, operational, and financial start add weight to the existing robotics- and efficiency-focused investment narrative. Building on these earnings beats and management’s confident tone, we’ll examine how Zimmer Biomet’s early-year momentum may influence...

In the world of robotic surgery, one company is both the undisputed leader and the most expensive name on the shelf, forcing investors to ask if operational brilliance is worth the high price of admission.

ZBH heads into Q2 earnings with expectations of modest revenue growth as investors watch demand trends across knees, hips and robotics.

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 2.3% and

Intuit downgrade, Intuitive Surgical upgraded: Wall Street's top analyst calls

Wall Street analysts are busy reshuffling their ratings ahead of the Fed meeting, with surprise double-upgrades, dramatic target cuts, and fresh initiations spanning surgical robots to cybersecurity. Find out which names made the biggest moves today.

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the surgical equipment & consumables - diversified industry, including Zimmer Biomet (NYSE:ZBH) and its peers.

The robotic surgery leader's shares have pulled back, forcing investors to weigh a solid recovery record against new questions in its most important market.

Here’s what analysts are expecting out of Zimmer Biomet’s upcoming Q2 earnings report.

At $353, Intuitive Surgical (ISRG) is being priced to deliver 14.1% revenue growth annually for the next 4 years simply to defend today's 42.1x multiple. That sits below the 21% the business is currently growing at, which is the unusual part. The multiple has already priced in a slowdown that has not yet appeared.

You can be forgiven for doing a double-take on Intuitive Surgical (ISRG) on Friday. The company posted second-quarter revenue of $2.89 billion, up 19% from a year ago and comfortably ahead of Wall Street estimates. Yet the stock ended the day down 14.1%, closing at a new 52-week low.

The surgical robotics giant beat estimates, but a moderation in its core US market has investors questioning the whole story.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

Chintan Desai, formerly of Alcon and GE HealthCare, has experience leading medtech teams in the region.

Find insight on Johnson & Johnson, Roche Holding, Novartis and more in the latest Market Talks covering health care.

Intuitive Surgical's powerful growth is running headlong into some serious market challenges, and how management framed the collision tells you everything about the real risks.

Zimmer Biomet Holdings has appointed Chintan Desai as president of its Asia Pacific region, effective July 14, 2026, succeeding long-serving leader Sang Yi after a transition period ending August 28, 2026. Desai’s three decades of MedTech and regional leadership experience across Asia Pacific, spanning Alcon and GE Healthcare, could meaningfully influence Zimmer Biomet’s execution in one of its most important international healthcare markets. Now we’ll examine how Desai’s appointment to lead...

Zimmer Biomet Holdings (ZBH) drew investor attention after appointing Chintan Desai as president of its Asia Pacific region, a key geography for the medical technology company’s global footprint and long term plans. See our latest analysis for Zimmer Biomet Holdings. The executive change comes as Zimmer Biomet Holdings trades at US$91.03, with a 7 day share price return of 1.81% and a 30 day share price return of 2.78%, while the 1 year total shareholder return has declined 2.17% and the 3...

Here is a way to get paid a meaningful income now on your Intuitive Surgical shares, cash you keep no matter what, in exchange for capping your gains at a price above today's.

This is a product-cycle year for Intuitive Surgical. The company's growth is fueled by hospitals and surgeons adopting its new da Vinci 5 and existing Ion robotic systems.